Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-01 · accession 0000950170-25-032248 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-04 | 2025-03-01 | NTLA | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +136.0K | 1.08M | +14% | $0 |
| D | 2025-03-04 | 2025-03-01 | NTLA | LEONARD JOHN M | Pres, CEO, Dir | A - Grant | $0.00 | +196.0K | 196.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-01 | A | A | 136,000 | $0.00 | 1,077,115 | D | — | — | (F1) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| 2 | Derivative | Stock Option (right to buy) | 2025-03-01 | A | A | 196,000 | $0.00 | 196,000 | D | $10.09 · — to 2035-02-28 | 196,000 Common Stock | (F3) This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |